Advanced search
Publication Cover
mAbs Volume 3, 2011 - Issue 3
Submit an article Journal homepage
2,581
Views
16
CrossRef citations to date
0
Altmetric
Perspective

Intellectual property protection

Strategies for antibody inventions

Ulrich Storz Senior Partner with Michalski Huettermann Patent Attorneys; Duesseldorf, GermanyCorrespondence[email protected]
Pages 310-317 | Received 28 Feb 2011, Accepted 18 Mar 2011, Published online: 01 May 2011

References

  • McCabe K. Guardians at the gate: Patent protection for therapeutic monoclonal antibodies-part 1. mAbs 2009; 1:382 - 384
  • www.epo.org/law-practice/case-law-appeals/search.html
  • EPO Technical Board decision T0601/05 2009; EPO Board of appeal decisions database T0601/05
  • Köhler GF, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 497
  • EPO Technical Board decision T0018/09 2009; EPO Board of appeal decisions database T0018/09
  • Eli Lilly and Company vs. Human Genome Sciences, [2008] EWHC 1903 (Pat), 2008 Bailii EWHC 1903
  • Centocor Ortho Biotech, Inc., v. Abbott Labs, 07-CV-0139, 2011 US App. LEXIS 3514
  • Ariad Pharmaceuticals, Inc., v. Eli Lilly and Company, 598 F.3d 1336, 2010 US App. LEXIS 5966
  • Generics UK vs. Daiichi, [2008] EWHC 2413 (Pat), 2008 Bailii EWHC 2413
  • Escitalopram, Xa ZR 130/07 (BPatG), 2009. GRUR 2010; 123
  • Forest Labs., Inc., v. Ivax Pharm., Inc., 501 F.3d 1263, 2007 US App. LEXIS 21165
  • Dr. Reddy's vs. Eli Lilly and Company, [2008] EWHC 2345 (Pat), 2008 Bailii EWHC 2345
  • Olanzapin X ZR 89/07 (BPatG) 2008. GRUR 2009; 382
  • Eli Lilly & Co., v. Zenith Goldline Pharm., Inc., 05-1396, 05-1429, 05-1430, 2007 US App. LEXIS 8750
  • Storz U. Kontermann R, Duebel S. IP Issues in the Therapeutic Antibody Industry. Antibody Engineering 2010; 2nd edition Springer 517 - 581
  • Guideline on similar biological medicinal products containing monoclonal antibodies (EMA/CHMP/BMWP/403543/2010), and Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (EMA/CHMP/BMWP/86289/2010) www.ema.europa.eu
  • Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985 - 990
  • Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov 2006; 5:993 - 996
  • Noelle v. Lederman, 355 F.3d 1343, 2004 US App. LEXIS 774
  • EPO Technical Board decision T0542/95. 1999 EPO Board of appeal decisions database T0542/95
  • Denlinger CS, et al. A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. J Clin Oncol (Meeting Abstracts) 2010; 5 28:15
  • Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245 - 255

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.